natgillin/translations-raw huggingface dataset:
The proportion of female patients in whom laxatives fail to provide adequate relief treated with the recommended dose of 2 mg Resolor (n=458) that reached an average of ≥ 3 SCBM per week was 31.0% (week 4) and 24.7% (week 12), versus 8.6% (week 4) and 9.2% (week 12) on placebo.
Razmerje bolnic, pri katerih laksativ ni privedel do ustreznega olajšanja, zdravljenih s priporočenim odmerkom 2 mg zdravila Resolor (n = 458), ki so dosegle ≥ 3 SCBM na teden, je bil 31,0 % (4. teden) in 24,7 % (12 teden) v primerjavi z 8,6 % (4. teden) in 9,2 % (12. teden) v primerjavi s placebom.
The proportion of IKERVIS-treated patients with a 3-grade improvement in CFS score at Month 6 (from 4 to 1) was 28.8%, compared to 9.6% of vehicle-treated subjects, but this was a post-hoc analysis, which limits the robustness of this outcome.
Delež bolnikov, zdravljenih z zdravilom IKERVIS, s 3-stopenjskim izboljšanjem rezultata po CFS v 6. mesecu (od 4 do 1), je bila 28,8 % v primerjavi z 9,6 % oseb, zdravljenih z vehiklom, vendar je bila to analiza post-hoc, ki omejuje robustnost izida.
The proportion of ILD-type events with a fatal outcome was 38.6%.
Delež dogodkov tipa IBP s smrtnim izidom je bil 38,6 %.
The proportion of patients achieving a DAS28 clinical remission (DAS28 < 2.6) was significantly higher in patients receiving tocilizumab (28–34%) compared to 1–12% of control patients at 24 weeks.
Delež bolnikov, ki so dosegli klinično remisijo glede na DAS28 (DAS28 < 2,6), je bil po 24 tednih značilno večji med bolniki, ki so dobivali tocilizumab (28–34 %), kot med kontrolnimi bolniki (1–12 %).
The proportion of patients achieving a modified PsA response criteria (PsARC) response was also significantly greater in the ustekinumab groups compared to placebo at week 24.
Tudi delež bolnikov, ki so dosegli odziv po modificiranih merilih odziva na zdravljenje psoriatičnega artritisa (PsARC- Psoriatic Arthritis treatment Response Criteria), je bil po 24 tednih značilno večji v skupini, ki je prejemala ustekinumab v primerjavi s placebom.
The proportion of patients achieving a modified PsA Response Criteria (PsARC) response was greater in the Cosentyx-treated patients (38.4%, 62.0% and 63.0% for 75 mg, 150 mg and 300 mg, respectively) compared to placebo (29.6%) at Week 24.
Delež bolnikov, ki so po 24 tednih zdravljenja dosegli odziv po spremenejenih kriterijih za psoriatični artritis (angl. modified PsA Response Criteria, PsARC), je bil večji v skupini z zdravilom Cosentyx (38,4%, 62,0% oziroma 63,0% pri odmerkih 75 mg, 150 mg oziroma 300 mg) v primerjavi z uporabo placeba (29.6%).
The proportion of patients achieving HbA1c < 7 % at week 24 for add-on therapy with dapagliflozin to saxagliptin plus metformin trial was higher in the saxagliptin plus dapagliflozin plus metformin group 35.3 % (95 % CI [28.2, 42.2]) compared to the placebo plus dapagliflozin plus metformin group 23.1 % (95 % CI [16.9, 29.3]).
Delež bolnikov, ki so dosegli HbA1c < 7,0 % do 24. tedna preskušanja dodatnega zdravljenja z dapagliflozinom, dodanega kombinaciji saksagliptina in metformina, je bil večji v skupini s kombinacijo saksagliptina, dapagliflozina in metformina (35,3 %; 95 % IZ: 28,2, 42,2) kot v skupini s kombinacijo placeba, dapagliflozina in metformina (23,1 %; 95 % IZ: 16,9, 29,3).
The proportion of patients achieving HbA1c < 7.0 % at Week 24 in the add-on therapy with saxagliptin to dapagliflozin plus metformin trial was higher in the saxagliptin plus dapagliflozin plus metformin group 38.0 % (95 % CI [30.9, 45.1]) compared to the placebo plus saxagliptin plus metformin group 12.4 % (95 % CI [7.0, 17.9]).
Delež bolnikov, ki so 24. teden dosegli HbA1c < 7,0 % v preskušanju, v katerem je bil saksagliptin dodan dapagliflozinu in metforminu, je bil večji v skupini s kombinacijo saksagliptina, dapagliflozina in metformina (38,0 %; 95 % IZ: 30,9-45,1) kot v skupini s kombinacijo placeba, saksagliptina in metformina (12,4 %; 95 % IZ: 7,0-17,9).
The proportion of patients achieving PASI-50, -75 and -90 responses, and sPGA score of clear (0) or almost clear (1), are presented in Table 4 below.
Delež bolnikov, ki so dosegli odzive PASI-50, -75 in -90 in rezultat sPGA čista (0) ali skoraj čista (1), so prikazani v preglednici 4 v nadaljevanju.
The proportion of patients alive at 12 months was 24% for DepoCyte versus 19% for unencapsulated cytarabine.
Delež živih bolnikov po 12 mesecih je bil 24% pri zdravilu DepoCyte ter 19% pri neinkapsuliranemu citarabinu.
The proportion of patients experiencing adverse events (AE) was similar in the patients aged 65 years and those aged 65 years.
Delež bolnikov, ki so se jim pojavili neželeni učinki, je bil med mlajšimi od 65 let podoben kot med starimi 65 let ali več.
The proportion of patients experiencing AEs was similar in those aged <65 years and those aged ≥65 years in both studies.
Deleži bolnikov z neželenimi dogodki so bili v obeh študijah pri tistih, ki so bili stari manj kot 65 let, približno enaki kot pri tistih, ki so bili stari najmanj 65 let.
The proportion of patients having an RFBM within 4 hours of the first dose was 34.2% in the combined methylnaltrexone bromide group versus 9.9% in the placebo group (p<0.001).
Delež bolnikov z iztrebljanjem brez rešilnega odvajala v 4 urah po prvem odmerku je bil 34,2 % v kombinirani skupini z metilnaltreksonijevim bromidom v primerjavi z 9,9 % v skupini s placebom (p < 0,001).
The proportion of patients treated with etanercept who developed anticardiolipin antibodies was similarly increased compared to placebo- treated patients.
Delež bolnikov, ki so razvili protitelesa proti kardiolipinu, je bil podobno povečan pri etanerceptu v primerjavi s placebom.
The proportion of patients who discontinued treatment due to adverse events during the controlled trials was 4.4% for patients treated with Cimzia and 2.7% for patients treated with placebo.
V okviru nadzorovanih raziskav je zaradi neželenih učinkov zdravljenje prekinilo 4,4 % bolnikov, ki so prejemali zdravilo Cimzia, in 2,7 % tistih, ki so dobivali placebo.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated patients.
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje med dvojno slepim, s placebom kontroliranim delom študij, ki podpirajo vlogo za pridobitev dovoljenja za promet, je bil 5,9 % v skupini, ki je prejemala zdravilo Humira, in 5,4 % v kontrolni skupini.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I−IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients.
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje med dvojno slepim, kontroliranim delom raziskav I-IX, CLASSIC I, GAIN in CHARM, je bil 5,7% v skupini, ki je prejemala Trudexo, in 5,3% v kontrolni skupini.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I−IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients.
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje med dvojno slepim, kontroliranim delom raziskav I–IX, CLASSIC I, GAIN in CHARM, je bil 5,7% v skupini, ki je prejemala Trudexo, in 5,3% v kontrolni skupini.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I−IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients.
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje med dvojno slepim, s placebom kontroliranim delom raziskav I–IX, CLASSIC I, GAIN in CHARM, je bil 5,7% v skupini, ki je prejemala Trudexo, in 5,3% v kontrolni skupini.
The proportion of patients who discontinued treatment due to adverse events was 9% for vedolizumab-treated patients and 10% for placebo-treated patients.
Zaradi neželenih učinkov je bilo treba zdravljenje prekiniti pri 9 % bolnikov, ki so prejemali vedolizumab, in 10 % bolnikov, ki so prejemali placebo.
The proportion of patients who discontinued treatment due to adverse reactions was 7% for both Benlysta-treated and placebo-treated patients.
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje, je bil med prejemniki zdravila Benlysta in med prejemniki placeba 7 %.
The proportion of patients who discontinued treatment due to ARs was 3.3% for abatacept- treated patients and 2.0% for placebo-treated patients.
Zaradi neželenih učinkov zdravila je bilo zdravljenje prekinjeno pri 3,3% bolnikov, ki so prejemali abatacept in 2,0% bolnikov, ki so prejemali placebo.
The proportion of patients who experienced a systolic blood pressure value >140 mmHg or a diastolic blood pressure >90 mmHg on at least two occasions was 3.4% and 1.5% in patients treated with lumacaftor/ivacaftor, respectively, compared with 1.6% and 0.5% in patients who received placebo (see section 4.4).
Delež bolnikov, ki so imeli ob vsaj dveh priložnostih vrednost sistoličnega krvnega tlaka >140 mm Hg ali diastoličnega krvnega tlaka >90 mm Hg , je bil 3,4 % oziroma 1,5 % pri bolnikih, zdravljenih z lumakaftorjem/ivakaftorjem, v primerjavi z 1,6 % oziroma 0,5 % pri bolnikih, ki so prejemali placebo (glejte poglavje 4.4).
The proportion of patients who had both a reduction in weight and HbA1c ranged from 70 to 79 % (the proportion of patients who had a reduction of HbA1c ranged from 88 to 96 %).
Delež bolnikov, pri katerih je prišlo do zmanjšanja telesne mase in HbA1c, je bil med 70 in 79 % (delež bolnikov, pri katerih je prišlo do zmanjšanja HbA1c je bil 88 do 96 %).
The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.
Odstotek bolnikov, ki so imeli povišane vrednosti ALT po zdravljenju v povezavi s povišanjem ravni bilirubina, je bil majhen in podoben pri bolnikih, ki so jemali bodisi lamivudin bodisi placebo.
The proportion of patients who had undetectable levels of HIV in their blood was about 45% when Celsentri was added to optimised background therapy compared with 23% of the patients receiving optimised background therapy only.
Približno 45 % bolnikov, ki so poleg optimizirane osnovne terapije jemali še zdravilo Celsentri, je imelo v krvi nezaznavne ravni virusa HIV, v primerjavi s 23 % bolnikov, ki so prejemali samo optimizirano osnovno terapijo.
The proportion of patients who permanently discontinued treatment due to adverse events was 0%,
Delež bolnikov, ki so zaradi neželenih učinkov trajno prekinili zdravljenje, je bil 0 %, < 1 % oz.
The proportion of patients who responded to treatment was therefore similar in the two groups, but when only the damage to the cornea was considered, Ikervis was significantly better than the vehicle at reducing it.
Delež bolnikov, ki so se odzvali na zdravljenje, je bil torej v obeh skupinah podoben, ko so primerjali samo poškodbo roženice, pa je bilo zdravilo Ikervis pri zmanjšanju poškodbe znatno učinkovitejše od vehikla.
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 12 was greater for Incruse 55 micrograms (44%) compared with placebo (26%) in the 12-week study.
Delež bolnikov, ki so se odzvali z vsaj minimalno klinično pomembno razliko seštevka SGRQ (ta je bila opredeljena kot znižanje za 4 enote v primerjavi z izhodiščem) po 12 tednih, je bil v 12-tedenski raziskavi z zdravilom Incruse večji (44 %) kot s placebom (26 %).
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 24 was greater for ANORO (49%) compared with placebo (34%) and each monotherapy component (44% for umeclidinium and 48% for vilanterol).
Po 24 tednih zdravljenja je bil delež bolnikov, ki so dosegli vsaj MCID v seštevku SGRQ (opredeljen kot zmanjšanje za 4 enote od izhodišča), pri zdravilu ANORO večji (49 %) v primerjavi s placebom (34 %) in monoterapijami (44 % – umeklidinij in 48 % – vilanterol).
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 24 was greater for LAVENTAIR (49%) compared with placebo (34%) and each monotherapy component (44% for umeclidinium and 48% for vilanterol).
Po 24 tednih zdravljenja je bil delež bolnikov, ki so dosegli vsaj MCID v seštevku SGRQ (opredeljen kot zmanjšanje za 4 enote od izhodišča), pri zdravilu LAVENTAIR večji (49 %) v primerjavi s placebom (34 %) in monoterapijami (44 % – umeklidinij in 48 % – vilanterol).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 12 was greater for Incruse (38%) compared with placebo (15%) in the 12- week study.
Delež bolnikov, ki so se odzvali z vsaj minimalno klinično pomembno razliko (MCID - minimum clinically important difference) 1 enote fokalnega seštevka TDI po 12 tednih, je bil v 12-tedenski študiji z zdravilom Incruse večji (38 %) kot s placebom (15 %).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 24 was greater for ANORO (58%) compared with placebo (41%) and each monotherapy component (53% for umeclidinium and 51% for vilanterol).
Delež bolnikov, ki so se odzvali z vsaj minimalno klinično pomembno razliko (MCID) 1 enoto fokalnega seštevka TDI po 24 tednih, je bil večji pri zdravljenju z zdravilom ANORO (58 %) kot pri dajanju placeba (41 %) ali vsake od obeh sestavin v monoterapiji (53 % za umeklidinij in 51 % za vilanterol).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 24 was greater for LAVENTAIR (58%) compared with placebo (41%) and each monotherapy component (53% for umeclidinium and 51% for vilanterol).
Delež bolnikov, ki so se odzvali z vsaj minimalno klinično pomembno razliko (MCID) 1 enoto fokalnega seštevka TDI po 24 tednih, je bil večji pri zdravljenju z zdravilom LAVENTAIR (58 %) kot pri dajanju placeba (41 %) ali vsake od obeh sestavin v monoterapiji (53 % za umeklidinij in 51 % za vilanterol).
The proportion of patients who were adequate relief responders was statistically significantly higher than placebo for Truberzi 100 mg twice daily over 6 month interval in both studies.
Delež bolnikov, ki so dosegli ustrezen odziv olajšanja simptomov, je bil statistično pomembno večji od placeba pri zdravilu Truberzi v odmerku 100 mg dvakrat dnevno v 6-mesečnem obdobju v obeh študijah.
The proportion of patients with a reported PR interval prolongation > 200 ms in this study ranged from 3/22 (14%) (day 3) to 8/21 (38%) (day14).
Delež bolnikov s poročanim podaljšanim intervalom PR > 200 ms je bil v tej študiji od 3/22 (14 %) (3. dan) do 8/21 (38 %) (14. dan).
The proportion of patients with a tumour response (CR, CRu, PR) was significantly higher (p< 0.0001 Chi-Square test) in the R-CVP group (80.9 %) than the CVP group (57.2 %).
Delež bolnikov z odgovorom na zdravljenje (CR, CRu – nepotrjeni popolni odgovor (complete response/uncomfirmed), PR) je bil značilno večji (p < 0,0001, test hi-kvadrat) v skupini R- CVP (80,9 %) kot v skupini CVP (57,2 %).
The proportion of patients with a tumour response (CR, CRu, PR) was significantly higher (p< 0.0001 Chi-Square test) in the R-CVP group (80.9%) than the CVP group (57.2%).
Delež bolnikov z odgovorom na zdravljenje (CR, CRu – nepotrjeni popolni odgovor (complete response/uncomfirmed), PR) je bil značilno večji (p < 0,0001, test hi-kvadrat) v skupini R- CVP (80,9 %) kot v skupini CVP (57,2 %).
The proportion of patients with ACR 20/50/70 (responses in Studies PALACE 1, PALACE 2 and PALACE 3, and the pooled data for studies PALACE 1, PALACE 2 and PALACE 3) for apremilast 30 mg twice daily at Week 16 are shown in Table 3.
Delež bolnikov z ACR 20/50/70 (odzivi v študijah PALACE 1, PALACE 2 in PALACE 3, in združeni podatki za študije PALACE 1, PALACE 2 in PALACE 3) za apremilast 30 mg dvakrat na dan v 16. tednu so prikazani v preglednici 3.
The proportion of patients with ACR 20/50/70 (responses in Studies PALACE 1, PALACE 2 and PALACE 3, and the pooled data for studies PALACE 1, PALACE 2 and PALACE 3) for apremilast 30 mg twice daily at Week 16 are shown in Table 3.
Deleži bolnikov z ACR 20/50/70 (odzivi v študijah PALACE 1, PALACE 2 in PALACE 3, in združeni podatki za študije PALACE 1, PALACE 2 in PALACE 3) za apremilast 30 mg dvakrat na dan v 16. tednu so prikazani v preglednici 3.
The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the prucalopride (25.1%) and placebo (20.7%) treatment groups.
V deležu bolnikov s povprečno tedensko frekvenco treh ali več spontanih popolnih odvajanj blata (SCBM – Spontaneous Complete Bowel Movement) (tj. odzivnih bolnikov) v 24-tedenski dvojno slepi fazi zdravljenja ni bilo statistično značilnih razlik (p = 0,367) med skupinama z zdravilom Resolor (25,1 %) in placebom (20,7 %).
The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the Resolor (25.1%) and placebo (20.7%) treatment groups.
V deležu bolnikov s povprečno tedensko frekvenco treh ali več spontanih popolnih odvajanj blata (SCBM – Spontaneous Complete Bowel Movement) (tj. odzivnih bolnikov) v 24-tedenski dvojno slepi fazi zdravljenja ni bilo statistično značilnih razlik (p = 0,367) med skupinama z zdravilom Resolor (25,1 %) in placebom (20,7 %).
The proportion of patients with at least 15 letters improvement from baseline BCVA in the study eye at week 8 was more than 6-fold higher with OZURDEX (42.9%) compared to
Delež bolnikov, ki so dosegli izboljšanje za vsaj 15 črk od izhodiščne vrednosti pri najboljši vidni ostrini s korekcijo (BCVA) v preiskovanem očesu v 8. tednu, je bil več kot 6-krat večji pri zdravljenju z zdravilom OZURDEX (42,9 %) kot pri placebu (6,6 %), p < 0,001.
The proportion of patients with at least one grade 3 or 4 liver-associated laboratory toxicity was 8.3% for nevirapine twice daily and 4.5% for efavirenz.
Delež bolnikov z najmanj enim laboratorijskim toksičnim učinkom 3. ali 4. stopnje, povezanim z jetri, je bil 8,3 % pri jemanju dveh odmerkov nevirapina na dan, in 4,5 % pri jemanju efavirenza.
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8 % in the zoledronic acid-treated group versus 49.6 % in the placebo group (p=0.003).
Delež bolnic z vsaj enim SRE (razen hiperkalciemije) je bil v skupini, zdravljeni z zoledronsko kislino 29,8 % v primerjavi s skupino s placebom, kjer je bil 49,6 % (p=0,003).
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid-treated group versus 49.6% in the placebo group (p=0.003).
Delež bolnic z vsaj enim SRE (razen hiperkalciemije) je bil v skupini, zdravljeni z zoledronsko kislino 29,8% v primerjavi s skupino s placebom, kjer je bil 49,6% (p=0,003).
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid-treated group versus 49.6% in the placebo group (p=0.003).
Delež bolnic z vsaj enim SRE (razen hiperkalciemije) je bil v skupini, zdravljeni z zoledronsko kislino, 29,8%, v skupini s placebom pa 49,6% (p=0,003).
The proportion of patients with detectable talimogene laherparepvec DNA in blood and urine was highest during the second cycle.
Delež bolnikov z zaznavno DNA talimogena laherparepveka v krvi in urinu je bil največji v drugem ciklusu.
The proportion of patients with IgG levels below the LLN was about 60% in the MabThera group throughout the 2 year treatment period, while it decreased in the observation group (36% after
Delež bolnikov s koncentracijo IgG pod spodnjo mejo normalne vrednosti je bil med 2-letnim zdravljenjem približno 60 % v skupini, ki je prejemala zdravilo MabThera, v opazovani skupini pa se je zmanjšal (36 % po dveh letih).
The proportion of patients with infections in C0168T72 was similar to that in the paediatric Crohn’s disease study (REACH) but higher than the proportion in the adults ulcerative colitis studies (ACT 1 and ACT 2).
Delež bolnikov z okužbami je bil v preskušanju C0168T72 podoben kot v študiji Crohnove bolezni pri pediatričnih bolnikih (REACH), a večji od deleža v študijah ulceroznega kolitisa pri odraslih bolnikih (ACT 1 in ACT 2).
The proportion of patients with KRAS wild-type tumours from the patient population evaluable for KRAS status comprised 58%.
Delež bolnikov s tumorji z nemutiranim tipom KRAS v populaciji bolnikov, ki so jim lahko ocenili KRAS, je bil 58- odstoten.
The proportion of responders was higher in subjects with a baseline viral load ≤ 100,000 copies/mL (78.6%, 22/28) as compared to those with a baseline viral load > 100,000 copies/mL (50.0%, 4/8).
Delež bolnikov z odzivom je bil večji pri preiskovancih z začetnim virusnim bremenom ≤ 100.000 kopij/ml (78,6%, 22/28) v primerjavi s preiskovanci z začetnim virusnim bremenom > 100.000 kopij/ml (50,0%, 4/8).
The proportion of Revestive-treated subjects achieving a 20% to 100% reduction of parenteral nutrition at Week 20 and 24 was statistically significantly different from placebo (27 out of
Delež preiskovancev, zdravljenih z zdravilom Revestive, ki so dosegli od 20 % do 100 % zmanjšanje parenteralne prehrane po 20 in 24 tednih, je bil statistično pomembno različen od placeba (27 od
The proportion of subjects reaching anti-HBs  10 mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix alone.
Delež oseb, ki so dosegle anti-HBs  10 mi.e./ml, je bil 98,3 % v primeru sočasnega cepljenja in 100 % v primeru cepljenja s cepivom Twinrix samim.
The proportion of subjects remaining in the study at Week 104 and Week 208 was 56.2% and 39.7% for the group treated with dapagliflozin and 50.0% and 34.6% for the group treated with glipizide.
Delež preiskovancev, ki so 104. in 208. teden še ostali v študiji, je bil v skupini z dapagliflozinom 56,2 % in 39,7 % ter v skupini z glipizidom 50,0 % in 34,6 %.
The proportion of subjects remaining in the study at Week 104 was 72.4% for the group treated with dapagliflozin 10 mg and 54.8% for the placebo group.
Delež preiskovancev, ki so 104. teden še ostali v študiji, je bil v skupini z mg dapagliflozina 72,4 % in v skupini s placebom 54,8 %.
The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dL,
Delež bolnikov, pri katerih je bilo treba zdraviti izbruh protina (v študijah APEX in FACT), je bil številčno nižji v skupinah, ki so dosegle povprečno vrednost urata v serumu po izhodišču < 6,0 mg/dl,
The proportion of subjects that seroconverted by 7 and by 28 days after the last immunisation was similar for both schedules.
Delež oseb, pri katerih je 7 do 28 dni po zadnji imunizaciji prišlo do serokonverzije, je bil pri obeh urnikih enak.
The proportion of subjects with clinically significant weight gain (≥ 7 % weight gain from baseline at Day 21) was 14.1 % for asenapine 2.5 mg twice daily, 8.9 % for asenapine 5 mg twice daily, and 9.2 % for asenapine 10 mg twice daily, compared to 1.1 % for placebo.
Odstotek preiskovancev s klinično pomembnim povečanjem telesne mase (t.j. z ≥ 7 % povečanjem telesne mase 21. dan, v primerjavi z začetnimi vrednostmi) je znašal 14,1 % za 2,5 mg asenapina dvakrat na dan, 8,9 % za 5 mg asenapina dvakrat na dan in 9,2 % za 10 mg asenapina dvakrat na dan, v primerjavi z 1,1 % za placebo.